The Trawick Group focuses on the design and evaluation of new compounds as therapeutic agents through enzyme kinetics and assays, mammalian cell culture, molecular modeling and protein purification. Specific applications include the discovery and development of vascular disrupting agents for the treatment of solid tumors and ophthalmologic disorders, and development of new compounds to treat metastatic cancer and Chagas’ disease.
